- Conditions
- Metabolic Syndrome
- Interventions
- Protandim
- Dietary Supplement
- Lead sponsor
- SomaLogic, Inc.
- Industry
- Eligibility
- 40 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 353
matching trials from the live ClinicalTrials.gov search.
- Conditions
- High-risk Prostate Cancer, Prostate Cancer
- Interventions
- HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
- Drug · Radiation · Procedure
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim
- Drug · Biological
- Lead sponsor
- David S Shulman, MD
- Other
- Eligibility
- 12 Years to 49 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Spasticity of the Upper and Lower Limb Due to Cerebral Causes
- Interventions
- IncobotulinumtoxinA
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Casdozokitug, Toripalimab, Bevacizumab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 22 more
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
- Interventions
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Drug
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- Pembrolizumab, Bevacizumab, Binimetinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
- Interventions
- NT 201, Placebo
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
- Conditions
- Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
- Interventions
- Ketogenic diet
- Drug
- Lead sponsor
- Heather Olson
- Other
- Eligibility
- 0 Days to 9 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stroke
- Interventions
- Protein, Placebo
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- NAFLD
- Interventions
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Dietary Supplement · Other
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Interventions
- JNJ-64619178
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
- Conditions
- Lower Respiratory Tract Infection (LRTI)
- Interventions
- Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician, Telephone Visit
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 8 more
- Conditions
- Covid19
- Interventions
- SCTA01, Placebo
- Drug · Other
- Lead sponsor
- Sinocelltech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Somers Point, New Jersey
- Conditions
- Spinal Cord Injury
- Interventions
- D-Cycloserine, Placebo, Training, Stimulation, Placebo Stimulation
- Drug · Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
- Interventions
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel, sargramostim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
- Interventions
- Botox injection, Saline injection
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Osteoporosis, Spinal Cord Injury
- Interventions
- Denosumab, Placebo (identical Denosumab volume of normal saline)
- Drug
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • The Bronx, New York
- Conditions
- Heart Failure, Asymptomatic Systolic Dysfunction
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Exercise Recovery, Physical Performance Parameters, Muscle Damage, Cognition, Blood Biomarkers, Stress
- Interventions
- Pork-Based Protein Ready-to-Eat Meals, Plant-Based Protein Ready-to-Eat Meals, Carbohydrate-Focused Lower-Protein Ready-to-Eat Meals
- Other
- Lead sponsor
- Sam Houston State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Fort Worth, Texas • Huntsville, Texas
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
- Drug · Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Irvine, California • Orange, California + 60 more